Cover Image
市場調查報告書

全球胰島素給藥設備市場未來預測

Global Insulin Delivery Devices Market Outlook 2018

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 274044
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
全球胰島素給藥設備市場未來預測 Global Insulin Delivery Devices Market Outlook 2018
出版日期: 2014年11月01日 內容資訊: 英文 120 Pages
簡介

2013年的全球糖尿病患者數是3億8200萬人。2030年,一般預期此患者數將達到5億5200萬人。還有胰島素給藥設備市場,2013年是104億美金。該市場,預計到2018年以8.5%的年複合成長率擴大。

本報告提供全球胰島素給藥設備 (胰島素給藥裝置) 市場相關調查分析、市場概要、推動市場要素、各地區、各設備預測、新產品的開發趨勢相關驗證、主要企業簡介等資訊。

第1章 分析師的見解

第2章 分析方法

第3章 全球胰島素市場概要

第4章 主要市場發展因素

第5章 主要市場發展阻礙要素

第6章 全球胰島素給藥設備市場預測

  • 調查項目
    • 疾病盛行率
    • 市場分析
    • 法規概要
  • 美國
  • 日本
  • 中國
  • 巴西
  • 印度

第7章 胰島素給藥設備:現在/未來預測

  • 調查項目
    • 功能及技術
    • 優點與弱點
    • 市場分析
    • 主要企業產品
  • 胰島素筆針
  • 胰島素幫浦
  • 胰島素注射器
  • 胰島素噴射注射器

第8章 新興設備

  • 置入式胰島素幫浦
  • 胰島素吸入器
  • 口服胰島素/胰島素藥丸
  • 胰島素貼片

第8章 主要企業

  • Novo Nordisk
  • Eli Lilly
  • Medtronic
  • Becton Dickinson
  • Sanofi-Aventis
  • F. Hoffmann La Roche
  • Insulet Corporation
  • Ypsomed Holding AG
  • Johnson and Johnson
  • B. Braun Melsungen AG
  • Abbott Laboratories

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of RNCOS' current study.

In our latest research study “Global Insulin Delivery Devices Market Outlook 2018”, RNCOS' analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. The market, which stood at US$ 10.4 Billion in 2013, is expected to grow at a CAGR of 8.5% during 2013-2018.

Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. The analysis will help readers to assess the current market penetration for various devices in different regions, which vary significantly due to consumer preferences.

RNCOS' study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Insulin Market Overview to 2018

4. Industry Trends and Drivers

  • 4.1. Rising Popularity of Artificial Pancreas
  • 4.2. Home Infusion Therapy Gaining Importance in Treatment of Diabetes
  • 4.3. Modifications in Insulin Delivery through Nanoparticles and Polymers
  • 4.4. Increasing Prevalence of Diabetes
  • 4.5. Rising Awareness among People about Diabetes Care
  • 4.6. Improved Access and Lower Insulin Prices in the Developing World
  • 4.7. Asian Markets Offer Considerable Growth Potential

5. Key Market Restraints

  • 5.1. Risk and Complications Associated with Delivery of Insulin
  • 5.2. High Cost of Insulin Analog
  • 5.3. Traditional Remedies for Diabetes Care

6. Global Insulin Delivery Devices Market Outlook to 2018

  • 6.1. US
    • 6.1.1. Prevalence
    • 6.1.2. Market Analysis
    • 6.1.3. Regulatory Overview
  • 6.2. Japan
    • 6.2.1. Prevalence
    • 6.2.2. Market Analysis
    • 6.2.3. Regulatory Overview
  • 6.3. China
    • 6.3.1. Prevalence
    • 6.3.2. Market Analysis
    • 6.3.3. Regulatory Overview
  • 6.4. Brazil
    • 6.4.1. Prevalence
    • 6.4.2. Market Analysis
    • 6.4.3. Regulatory Overview
  • 6.5. India
    • 6.5.1. Prevalence
    • 6.5.2. Market Analysis
    • 6.5.3. Regulatory Overview

7. Insulin Delivery Devices: Current and Future Outlook to 2018

  • 7.1. Insulin Pens
    • 7.1.1. Mechanism and Technologies
    • 7.1.2. Pros and Cons
    • 7.1.3. Market Analysis
    • 7.1.4. Key Players and Products
  • 7.2. Insulin Pumps
    • 7.2.1. Mechanism and Technologies
    • 7.2.2. Pros and Cons
    • 7.2.3. Market Analysis
    • 7.2.4. Key Players and Products
  • 7.3. Insulin Syringes
    • 7.3.1. Mechanism and Technologies
    • 7.3.2. Pros and Cons
    • 7.3.3. Market Analysis
    • 7.3.4. Key Players and Products
  • 7.4. Insulin Jet Injectors
    • 7.4.1. Mechanism and Technologies
    • 7.4.2. Pros and Cons
    • 7.4.3. Market Analysis
    • 7.4.4. Key Players and Products

8. Emerging Devices

  • 8.1. Implantable Insulin Pumps
  • 8.2. Insulin Inhalers
  • 8.3. Oral Insulin/Insulin Pill
  • 8.4. Insulin Patch

9. Key Players

  • 9.1. Novo Nordisk
  • 9.2. Eli Lilly
  • 9.3. Medtronic
  • 9.4. Becton Dickinson
  • 9.5. Sanofi-Aventis
  • 9.6. F. Hoffmann La Roche
  • 9.7. Insulet Corporation
  • 9.8. Ypsomed Holding AG
  • 9.9. Johnson and Johnson
  • 9.10. B. Braun Melsungen AG
  • 9.11. Abbott Laboratories

List of Figures:

  • Figure 3-1: Global - Number of Diabetic Patients (Million), 2013 & 2030
  • Figure 3-2: Global - Insulin Market (Billion US$), 2013-2018
  • Figure 3-3: Global - Insulin Market by Type of Packaging (%), 2013
  • Figure 3-4: Global - Insulin Market by Region (%), 2013
  • Figure 3-5: Global - Insulin Market by Player (%), 2013
  • Figure 6-1: Global - Insulin Delivery Devices Market (Billion US$), 2013-2018
  • Figure 6-2: Global - Insulin Delivery Devices Market by Segment (%), 2013
  • Figure 6-3: US - Insulin Delivery Devices Market (Billion US$), 2013-2018
  • Figure 6-4: US - Insulin Delivery Devices Market by Segment (%), 2013
  • Figure 6-5: US - Insulin Delivery Devices Market by Segment (%), 2018
  • Figure 6-6: US - Insulin Pen Market (Billion US$), 2013-2018
  • Figure 6-7: US - Insulin Syringe Market (Million US$), 2013-2018
  • Figure 6-8: US - Insulin Pump Market (Million US$), 2013-2018
  • Figure 6-9: US - Insulin Jet Injector Market (Million US$), 2013-2018
  • Figure 6-10: Japan - Insulin Delivery Devices Market (Billion US$), 2013-2018
  • Figure 6-11: Japan - Insulin Pen Market (Million US$), 2013-2018
  • Figure 6-12: Japan - Insulin Syringe Market (Million US$), 2013-2018
  • Figure 6-13: China - Insulin Delivery Devices Market (Million US$), 2013-2018
  • Figure 6-14: China - Insulin Pen Market (Million US$), 2013-2018
  • Figure 6-15: China - Insulin Syringe Market (Million US$), 2013-2018
  • Figure 6-16: Brazil - Insulin Delivery Devices Market (Million US$), 2013-2018
  • Figure 6-17: Brazil - Insulin Pen Market (Million US$), 2013-2018
  • Figure 6-18: Brazil - Insulin Syringe Market (Million US$), 2013-2018
  • Figure 6-19: India - Insulin Delivery Devices Market (Million US$), 2013-2018
  • Figure 6-20: India - Insulin Pen Market (Million US$), 2013-2018
  • Figure 6-21: India - Insulin Syringe Market (Million US$), 2013-2018
  • Figure 7-1: Global - Insulin Pen Market (Billion US$), 2013-2018
  • Figure 7-2: Global - Insulin Pen Market by Region (%), 2013
  • Figure 7-3: Global - Insulin Pen Market by Region (%), 2018
  • Figure 7-4: Global - Insulin Pump Market (Million US$), 2013-2018
  • Figure 7-5: Global - Share of Medtronic in Insulin Pumps Market (2010)
  • Figure 7-6: Global - Insulin Syringes Market (Million US$), 2013-2018
  • Figure 7-7: Global - Insulin Syringes Market by Region (%), 2013
  • Figure 7-8: Global - Insulin Syringes Market by Region (%), 2018
  • Figure 7-9: Global - Insulin Jet Injectors Market (Million US$), 2013-2018
  • Figure 9-1: Novo Nordisk - Share of Diabetic Products of by Value (2013)
  • Figure 9-2: Novo Nordisk - Sales by Geographic Regions (%), 2013
  • Figure 9-3: Eli Lilly - Sales by Business Segments (%), 2013
  • Figure 9-4: Eli Lilly - Sales by Geographic Regions (%), 2013
  • Figure 9-5: Medtronic - Sales by Business Segments (%), 2013
  • Figure 9-6: Medtronic - Sales by Geographic Regions (%), 2013
  • Figure 9-7: BD Global - Sales by Business Segments (%), 2013
  • Figure 9-8: BD Medical - Sales by Business Segments (%), 2013
  • Figure 9-9: BD Global - Sales by Geographic Regions (%), 2013
  • Figure 9-10: Sanofi-Aventis - Sales by Geographic Regions (%), 2013
  • Figure 9-11: Roche - Sales by Business Segments (%), 2013
  • Figure 9-12: Roche - Sales of In-Vitro Diagnostics by Segments (%), 2013
  • Figure 9-13: Roche - Sales by Geographic Regions (%), 2013
  • Figure 9-14: Ypsomed - Sales by Geographic Regions (%), 2013
  • Figure 9-15: J&J - Sales by Business Segments (%), 2013
  • Figure 9-16: B.Braun - Sales by Geographic Regions (%), 2013
  • Figure 9-17: Abbott - Sales by Business Segments (%), 2013
  • Figure 9-18: Abbott - Sales of Medical Devices by Segments (%), 2013
  • Figure 9-19: Abbott - Sales by Geographic Regions (%), 2013

List of Tables:

  • Table 3-1: Global - Diabetic Population of Top 10 Countries (Million), 2013 & 2030
  • Table 4-1: Commercially available Insulin Pumps
  • Table 5-1: Risk factors associated with Insulin Pumps
  • Table 5-2: Risk factors associated with Insulin Pen
  • Table 6-1: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 6-2: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 6-3: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 6-4: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 6-5: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2013 & 2030
  • Table 7-1: Global - Key Insulin Pen Products by Company
  • Table 7-2: Global - Key Insulin Syringes Products by Company
  • Table 9-1: Novo Nordisk - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-2: Novo Nordisk - Diabetes Product Sales by Geographic Regions (Million US$), 2011-2013
  • Table 9-3: Eli Lilly - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-4: Eli Lilly - Sales by Geographic Regions (Million US$), 2011-2013
  • Table 9-5: Medtronic - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-6: BD Global - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-7: BD Medical - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-8: Sanofi-Aventis - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-9: Insulet Corporation - Sales of Insulin Pumps (Million US$), 2011-2013
  • Table 9-10: J&J - Sales by Business Segments (Million US$), 2011-2013
  • Table 9-11: J&J - Sales of Medical Devices & Diagnostics by Segments (Million US$), 2011-2013
Back to Top